CN1195745C - 抗病毒大环化合物 - Google Patents

抗病毒大环化合物 Download PDF

Info

Publication number
CN1195745C
CN1195745C CNB998082600A CN99808260A CN1195745C CN 1195745 C CN1195745 C CN 1195745C CN B998082600 A CNB998082600 A CN B998082600A CN 99808260 A CN99808260 A CN 99808260A CN 1195745 C CN1195745 C CN 1195745C
Authority
CN
China
Prior art keywords
compound
heptadeca
pyridine
aminomethyl
trienyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB998082600A
Other languages
English (en)
Chinese (zh)
Other versions
CN1308617A (zh
Inventor
G·J·布里杰
E·M·伯林格
王忠仁
D·肖尔斯
R·T·斯基勒
D·E·博古茨基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arno Ahmed Co ltd
Genzyme Corp
Original Assignee
Anormed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anormed Inc filed Critical Anormed Inc
Publication of CN1308617A publication Critical patent/CN1308617A/zh
Application granted granted Critical
Publication of CN1195745C publication Critical patent/CN1195745C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ceramic Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Materials Engineering (AREA)
  • Structural Engineering (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CNB998082600A 1998-07-08 1999-07-08 抗病毒大环化合物 Expired - Fee Related CN1195745C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/111,895 US6506770B1 (en) 1996-06-06 1998-07-08 Antiviral compounds
US09/111,895 1998-07-08

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNB2005100094866A Division CN100339080C (zh) 1998-07-08 1999-07-08 抗病毒大环化合物

Publications (2)

Publication Number Publication Date
CN1308617A CN1308617A (zh) 2001-08-15
CN1195745C true CN1195745C (zh) 2005-04-06

Family

ID=22341015

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB998082600A Expired - Fee Related CN1195745C (zh) 1998-07-08 1999-07-08 抗病毒大环化合物
CNB2005100094866A Expired - Lifetime CN100339080C (zh) 1998-07-08 1999-07-08 抗病毒大环化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB2005100094866A Expired - Lifetime CN100339080C (zh) 1998-07-08 1999-07-08 抗病毒大环化合物

Country Status (17)

Country Link
US (6) US6506770B1 (enExample)
EP (1) EP1095031B1 (enExample)
JP (1) JP4637353B2 (enExample)
KR (1) KR100778134B1 (enExample)
CN (2) CN1195745C (enExample)
AP (1) AP1436A (enExample)
AU (1) AU767359B2 (enExample)
BR (1) BR9912524A (enExample)
CA (1) CA2336634C (enExample)
HU (1) HUP0102930A3 (enExample)
IL (1) IL140605A0 (enExample)
MX (1) MXPA01000137A (enExample)
NO (1) NO20010047L (enExample)
NZ (1) NZ509699A (enExample)
PL (1) PL345516A1 (enExample)
TR (1) TR200100030T2 (enExample)
WO (1) WO2000002870A1 (enExample)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506770B1 (en) 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
GB9511357D0 (en) * 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
US20050085555A1 (en) * 1997-08-21 2005-04-21 Murphy Michael A. Composition, synthesis and therapeutic applications of polyamines
US6365583B1 (en) 1999-02-02 2002-04-02 Anormed, Inc. Methods to enhance white blood cell count
EP1244648B1 (en) * 1999-12-17 2009-04-15 Genzyme Corporation Chemokine receptor binding heterocyclic compounds
RU2277092C2 (ru) * 2000-09-15 2006-05-27 Анормед, Инк. Гетероциклические соединения, их применение и фармацевтическая композиция для лечения состояний, опосредованных схсr4 и ccr5
NZ524421A (en) * 2000-09-15 2005-02-25 Anormed Inc Chemokine receptor binding heterocyclic compounds
US7052676B2 (en) * 2000-09-26 2006-05-30 The Regents Of The University Of Michigan Methods for inhibition of HIV replication using a small molecule inhibitor
US7169750B2 (en) * 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
ATE538785T1 (de) * 2001-07-31 2012-01-15 Genzyme Global S A R L Verfahren zur mobilisierung von vorläufer/stammzellen
CN1596255A (zh) * 2001-12-21 2005-03-16 阿诺麦德股份有限公司 具有强效的与趋化因子受体结合的杂环化合物
US7354932B2 (en) * 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US20030199464A1 (en) * 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
ATE453386T1 (de) * 2003-04-02 2010-01-15 Taigen Biotechnology Co Ltd Polyamin-verbindungen zur behandlung von chemokin-rezeptor-vermittelten krankheiten
US7504422B2 (en) 2003-04-02 2009-03-17 Taigen Biotechnology Co. Ltd. Polyamine compounds
US7291631B2 (en) 2003-04-11 2007-11-06 Genzyme Corporation CXCR4 chemokine receptor binding compounds
CA2517077C (en) 2003-04-22 2013-03-12 Anormed Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US7501518B2 (en) 2003-04-22 2009-03-10 Genzyme Corporation Methods of making 2,6-diaryl piperidine derivatives
JPWO2005051927A1 (ja) * 2003-11-26 2007-12-06 株式会社クレハ Ｈｉｖ−１感染末梢血単核球の刺激培養によるｃｄ４陽性ｔ細胞の培養方法、及びｈｉｖ−１の増殖阻害剤
BRPI0514343A (pt) * 2004-08-13 2008-06-10 Anormed Inc combinações de quimiocinas para mobilizar células progenitoras/tronco
US7501526B2 (en) 2005-01-20 2009-03-10 Taigen Biotechnology Synthesis of polyamine compounds
US8569280B2 (en) * 2005-04-25 2013-10-29 Immune Disease Institute Methods for the treatment of multiple myeloma
WO2006116185A2 (en) * 2005-04-25 2006-11-02 Cbr Institute For Biomedical Research, Inc. Methods for the treatment of multiple myeloma
JP2009504788A (ja) * 2005-08-19 2009-02-05 ジェンザイム・コーポレーション 化学療法の強化方法
CA2624138A1 (en) * 2005-09-29 2007-04-05 British Columbia Cancer Agency Branch Method and composition for increasing the engraftment efficiency of stem cells
EP1993584B1 (en) 2006-02-02 2012-05-30 Allergan, Inc. Inhibitors of CXCR4 activity for use in the treatment of ocular disorders
WO2007144720A2 (en) * 2006-06-12 2007-12-21 Pfizer Products Inc. Ccr5 antagonist for enhancing immune reconstitution and treating opportunistic infection in hiv patients
WO2008017025A2 (en) * 2006-08-02 2008-02-07 Genzyme Corporation Combination therapy
CA2659337A1 (en) * 2006-08-07 2008-02-14 Genzyme Corporation Combination therapy
US20090274687A1 (en) * 2008-05-02 2009-11-05 University Of Miami Attenuation of hypoxia induced cardiovascular disorders
WO2010088401A1 (en) * 2009-01-30 2010-08-05 Genzyme Corporation Methods and compositions for treating breast cancer
EP2424544A1 (en) * 2009-05-01 2012-03-07 GlycoMimetics, Inc. Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors
WO2012037034A1 (en) 2010-09-14 2012-03-22 Glycomimetics, Inc. E-selectin antagonists
GB201017345D0 (en) 2010-10-14 2010-11-24 Proximagen Ltd Receptor antagonists
WO2012061662A1 (en) * 2010-11-03 2012-05-10 Glycomimetics, Inc. Glycomimetic-peptidomimetic inhibitors of e-selectins and cxcr4 chemokine receptors
KR20200016407A (ko) 2011-05-16 2020-02-14 젠자임 코포레이션 Ｃｘｃｒ４ 길항제의 용도
CN103159690B (zh) * 2011-12-14 2015-03-25 朱靖华 对称大环胺化合物的结晶形式
EP3296310A1 (en) 2011-12-22 2018-03-21 GlycoMimetics, Inc. E-selectin antagonist compounds, compositions, and methods of use
US9867841B2 (en) 2012-12-07 2018-01-16 Glycomimetics, Inc. Compounds, compositions and methods using E-selectin antagonists for mobilization of hematopoietic cells
CN103058998B (zh) * 2013-01-16 2016-04-13 山东鲁北药业有限公司 一种amd3465的制备工艺
ES2754549T3 (es) 2014-12-03 2020-04-20 Glycomimetics Inc Inhibidores heterobifuncionales de E-selectinas y receptores de quimioquinas CXCR4
AU2016242118B2 (en) * 2015-04-02 2021-07-08 Proximagen, Llc Novel therapies for cancer
WO2017011517A1 (en) 2015-07-16 2017-01-19 Emory University Bis-amines, compositions, and uses related to cxcr4 inhibition
CN108135880A (zh) * 2015-10-19 2018-06-08 拉莫特特拉维夫大学有限公司 用于治疗神经退化性疾病的方法及组成物
JP6864296B2 (ja) 2015-12-14 2021-04-28 エックス４ ファーマシューティカルズ， インコーポレイテッド がんを処置する方法
CN109069486A (zh) 2015-12-14 2018-12-21 X4 制药有限公司 治疗癌症的方法
WO2017112894A1 (en) 2015-12-22 2017-06-29 X4 Pharmaceuticals, Inc. Methods for treating immunodeficiency disease
US11291678B2 (en) 2016-03-02 2022-04-05 Glycomimetics, Inc Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin
EP3440112A4 (en) 2016-04-08 2019-10-09 X4 Pharmaceuticals, Inc. METHOD FOR THE TREATMENT OF CANCER
EP3471716A1 (en) 2016-06-16 2019-04-24 Centre National De La Recherche Scientifique Cxcr4 receptor-binding compounds useful for increasing interferon level
JP7054529B2 (ja) 2016-06-21 2022-04-14 エックス４ ファーマシューティカルズ， インコーポレイテッド Ｃｘｃｒ４阻害剤およびその使用
WO2017223243A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
CN109640988A (zh) 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
WO2018031445A1 (en) 2016-08-08 2018-02-15 Glycomimetics, Inc. Combination of t-cell checkpoint inhibitors with inhibitors of e-selectin or cxcr4, or with heterobifunctional inhibitors of both e-selectin and cxcr4
CA3037850A1 (en) 2016-10-07 2018-04-12 Glycomimetics, Inc. Highly potent multimeric e-selectin antagonists
CA3054605A1 (en) 2017-03-15 2018-09-20 Glycomimetics, Inc. Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists
JP7412341B2 (ja) 2017-10-31 2024-01-12 エディジーン バイオテクノロジー インコーポレイテッド 造血幹細胞および前駆細胞の増幅のための組成物および方法
EP3703715A1 (en) 2017-10-31 2020-09-09 Magenta Therapeutics, Inc. Compositions and methods for hematopoietic stem and progenitor cell transplant therapy
EP3717013A1 (en) 2017-11-30 2020-10-07 GlycoMimetics, Inc. Methods of mobilizing marrow infiltrating lymphocytes and uses thereof
US10058573B1 (en) 2017-12-06 2018-08-28 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem cells
US11260079B2 (en) 2017-12-06 2022-03-01 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
KR20200096942A (ko) 2017-12-06 2020-08-14 마젠타 테라퓨틱스 인코포레이티드 조혈 줄기 및 자손 세포의 동원을 위한 투여 요법
CN109988153B (zh) * 2017-12-29 2021-11-19 深圳夏浠湾医药科技有限公司 一种川芎嗪衍生物及其制备方法和应用
CA3085356A1 (en) 2017-12-29 2019-07-04 Glycomimetics, Inc. Heterobifunctional inhibitors of e-selectin and galectin-3
CN111902411A (zh) 2018-01-03 2020-11-06 美真达治疗公司 用于扩增造血干细胞和祖细胞以及治疗遗传性代谢紊乱的组合物和方法
KR20200128025A (ko) 2018-03-05 2020-11-11 글리코미메틱스, 인크. 급성 골수성 백혈병 및 관련 병태의 치료 방법
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
US20220401481A1 (en) 2019-11-01 2022-12-22 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
CA3171250A1 (en) 2020-03-10 2021-09-16 E. Lynne KELLEY Methods for treating neutropenia
WO2021222313A1 (en) 2020-04-27 2021-11-04 Magenta Therapeutics, Inc. Methods and compositions for transducing hematopoietic stem and progenitor cells in vivo
EP4308694A1 (en) 2021-03-16 2024-01-24 Magenta Therapeutics, Inc. Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5021409A (en) 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
GB9105489D0 (en) 1991-03-15 1991-05-01 Johnson Matthey Plc Improvements in chemical compounds
GB9126677D0 (en) 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
GB9400411D0 (en) 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
US6506770B1 (en) 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
GB9511357D0 (en) * 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
WO2000009152A1 (en) 1998-08-14 2000-02-24 The University Of British Columbia Therapeutic chemokine receptor antagonists
WO1999047158A2 (en) 1998-03-13 1999-09-23 The University Of British Columbia Therapeutic chemokine receptor antagonists
ATE333896T1 (de) 1998-03-24 2006-08-15 Chugai Pharmaceutical Co Ltd Vaskularisierungsinhibitoren
WO1999065507A1 (en) * 1998-06-19 1999-12-23 The General Hospital Corporation Modulating platelet function
WO2000006086A2 (en) * 1998-07-31 2000-02-10 The Trustees Of Columbia University In The City Of New York Use of inhibitors of the activation of cxcr4 receptor by sdf-1 in treating rheumatoid arthritis
US6365583B1 (en) 1999-02-02 2002-04-02 Anormed, Inc. Methods to enhance white blood cell count
WO2005002522A2 (en) 2003-06-30 2005-01-13 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Compositions and methods for treating tissue ischemia
US7315917B2 (en) * 2005-01-20 2008-01-01 Sandisk Corporation Scheduling of housekeeping operations in flash memory systems

Also Published As

Publication number Publication date
MXPA01000137A (es) 2002-11-29
CN100339080C (zh) 2007-09-26
JP4637353B2 (ja) 2011-02-23
US20040235814A1 (en) 2004-11-25
AP1436A (en) 2005-06-22
NZ509699A (en) 2003-10-31
EP1095031A1 (en) 2001-05-02
HUP0102930A3 (en) 2002-06-28
AU4595999A (en) 2000-02-01
BR9912524A (pt) 2001-05-02
CA2336634A1 (en) 2000-01-20
US7414065B2 (en) 2008-08-19
CA2336634C (en) 2009-05-19
KR20010071764A (ko) 2001-07-31
KR100778134B1 (ko) 2007-11-27
US20080287454A1 (en) 2008-11-20
US7160872B2 (en) 2007-01-09
WO2000002870A1 (en) 2000-01-20
US7709486B2 (en) 2010-05-04
US20050154005A1 (en) 2005-07-14
AP2001002043A0 (en) 2001-03-31
NO20010047D0 (no) 2001-01-04
AU767359B2 (en) 2003-11-06
CN1308617A (zh) 2001-08-15
US6756391B2 (en) 2004-06-29
IL140605A0 (en) 2002-02-10
EP1095031B1 (en) 2013-08-21
NO20010047L (no) 2001-03-01
US6872714B1 (en) 2005-03-29
TR200100030T2 (tr) 2001-06-21
JP2002520323A (ja) 2002-07-09
CN1679562A (zh) 2005-10-12
HUP0102930A2 (hu) 2001-11-28
PL345516A1 (en) 2001-12-17
US6506770B1 (en) 2003-01-14
US20030018189A1 (en) 2003-01-23

Similar Documents

Publication Publication Date Title
CN1195745C (zh) 抗病毒大环化合物
CN1273451C (zh) 哌啶mch拮抗剂及其治疗肥胖症的用途
CN1190432C (zh) 作为5－htib拮抗药的哌嗪衍生物
CN1304375C (zh) 用作jnk抑制剂的吡唑并蒽酮及其衍生物和它们的组合物
CN1882578A (zh) 作为zap－70和/或syk抑制剂的2,4－二(杂)芳基氨基嘧啶衍生物
CN1761646A (zh) 大麻素受体配位体
CN1426411A (zh) 3－(二芳基亚甲基)－8－氮杂双环[3.2.1]辛烷衍生物
CN1422269A (zh) 1h－咪唑并吡啶衍生物
CN1852905A (zh) 具有n－取代的苯并咪唑基的c－kit抑制剂
CN1933834A (zh) 吲唑甲酰胺衍生物在制备用于治疗和预防疟疾的药物中的用途
CN1886380A (zh) 苯并咪唑化合物
CN1262678A (zh) 三唑化合物及其作为多巴胺－d3－配体的应用
CN1671666A (zh) Vegfr－2和vegfr－3抑制性的邻氨基苯甲酰胺吡啶化合物
CN1416421A (zh) 新的ccr5调节剂:苯并咪唑或苯并三唑
CN1845921A (zh) 金刚烷和氮杂双环－辛烷及壬烷衍生物、其制备方法及其作为dpp－iv抑制剂的用途
CN1387517A (zh) 作为环加氧酶－2抑制剂的5－芳基－1h－1,2,4－三唑化合物及含有它们的药物组合物
CN1402720A (zh) 用作免疫抑制剂的2,4－二氨基嘧啶化合物
CN1511151A (zh) 3-喹啉-2(1h)-亚基二氢吲哚-2-酮衍生物
CN1249052C (zh) 作为hiv逆转录酶抑制剂的吡唑衍生物
CN1726196A (zh) 基于吡嗪的微管蛋白抑制剂
CN1882571A (zh) 吡咯衍生物
CN101052634A (zh) 作为vegf受体激酶抑制剂的邻氨基苯甲酰胺吡啶脲
CN1906188A (zh) 作为igf－1r抑制剂的苯基－[4－(3－苯基－1h－吡唑－4－基)－嘧啶－2－基]－胺衍生物
CN1413205A (zh) 具有抗肿瘤活性的2－(1h－吲哚－3－基)－2－氧代－乙酰胺
CN1816541A (zh) Vr－1拮抗剂取代－1－酞嗪胺

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: ANORMED LTD.

Free format text: FORMER OWNER: ANORMED INC.

Effective date: 20140327

Owner name: GENZYME CORP.

Free format text: FORMER OWNER: ANORMED LTD.

Effective date: 20140327

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20140327

Address after: Massachusetts, USA

Patentee after: GENZYME Corp.

Address before: Nova Scotia Canada

Patentee before: Arno Ahmed Co.,Ltd.

Effective date of registration: 20140327

Address after: Nova Scotia Canada

Patentee after: Arno Ahmed Co.,Ltd.

Address before: British Columbia Canada

Patentee before: Anormed Inc.

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20050406

Termination date: 20150708

EXPY Termination of patent right or utility model